Video | 15 February 2020 Big pharma is double dipping 1 min RESEARCH AND DEVELOPMENT Medicines made with help from OUR taxes should be accessible to EVERYONE who needs them. SHARE this video and tell our leaders to stand up to Big Pharma’s double-dip profiteering. Share this message! Tell your leaders: We won’t pay twice for medicines any more. Share on Read, watch, share Filter by - Any -BlogEventsFeature storyInfographicIssue briefLetterNewsletterOpinion articlePress releaseReportResearch articleSpeechSpotlightStatementTechnical briefTopic overviewVideo Letter | 17 April 2026 Pandemic preparedness Research and development Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement Issue brief Issue brief | 09 April 2026 Research and development KenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape Photo credit: MSF/Martim Gray Pereira Press release Press release | 19 March 2026 Pandemic preparedness Research and development European Union MSF calls on EU to unlock progress in final Pandemic Agreement talks 2 min Letter Letter | 16 March 2026 Research and development European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all Report | 15 May 2025 HIV/AIDS Research and development South AfricaUnited States of America South Africa’s TB and HIV Research at Risk : A Call To Catalyze Urgent Action By Funders Photograph by Valérie Batselaere Statement Statement | 23 January 2025 Pandemic preparedness Antimicrobial resistance Intellectual property and trade Research and development Tropical & neglected diseases Vaccines MSF statement on US decision to withdraw from WHO Photograph by Alexandra Sadokova Press release Press release | 25 April 2024 Transparency Research and development Tuberculosis In precedent-setting move towards drug-development cost transparency, MSF reveals cost of its landmark TB clinical trial: €34 million 6 min Technical brief | 25 April 2024 Transparency Research and development Transparency CORE: Clinical Trial Cost Reporting Toolkit Load More
Letter | 17 April 2026 Pandemic preparedness Research and development Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Issue brief Issue brief | 09 April 2026 Research and development KenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Photo credit: MSF/Martim Gray Pereira Press release Press release | 19 March 2026 Pandemic preparedness Research and development European Union MSF calls on EU to unlock progress in final Pandemic Agreement talks 2 min
Letter Letter | 16 March 2026 Research and development European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Report | 15 May 2025 HIV/AIDS Research and development South AfricaUnited States of America South Africa’s TB and HIV Research at Risk : A Call To Catalyze Urgent Action By Funders
Photograph by Valérie Batselaere Statement Statement | 23 January 2025 Pandemic preparedness Antimicrobial resistance Intellectual property and trade Research and development Tropical & neglected diseases Vaccines MSF statement on US decision to withdraw from WHO
Photograph by Alexandra Sadokova Press release Press release | 25 April 2024 Transparency Research and development Tuberculosis In precedent-setting move towards drug-development cost transparency, MSF reveals cost of its landmark TB clinical trial: €34 million 6 min
Technical brief | 25 April 2024 Transparency Research and development Transparency CORE: Clinical Trial Cost Reporting Toolkit
